Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS...
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
About this item
Full title
Author / Creator
Yoshida, Yoichiro , Yamada, Takeshi , Kamiyama, Hirohiko , Kosugi, Chihiro , Ishibashi, Keiichiro , Yoshida, Hiroshi , Ishida, Hideyuki , Yamaguchi, Satoru , Kuramochi, Hidekazu , Fukazawa, Atsuko , Sonoda, Hiromichi , Yoshimatsu, Kazuhiko , Matsuda, Akihisa , Hasegawa, Suguru , Sakamoto, Kazuhiro , Otsuka, Toshiaki , Koda, Keiji , On behalf of the TAS CC3 Study Group and TAS CC3 Study Group
Publisher
Singapore: Springer Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Singapore
Subjects
More information
Scope and Contents
Contents
Background
TAS-102 improved the overall survival of metastatic colorectal cancer (CRC) patients with a median progression-free survival (PFS) in the RECOURSE trial. Subsequently, the combination of TAS-102 and bevacizumab was shown to extend the median PFS (C-TASK FORCE study). However, the study included patients who received second- and third-...
Alternative Titles
Full title
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
Authors, Artists and Contributors
Author / Creator
Yamada, Takeshi
Kamiyama, Hirohiko
Kosugi, Chihiro
Ishibashi, Keiichiro
Yoshida, Hiroshi
Ishida, Hideyuki
Yamaguchi, Satoru
Kuramochi, Hidekazu
Fukazawa, Atsuko
Sonoda, Hiromichi
Yoshimatsu, Kazuhiko
Matsuda, Akihisa
Hasegawa, Suguru
Sakamoto, Kazuhiro
Otsuka, Toshiaki
Koda, Keiji
On behalf of the TAS CC3 Study Group
TAS CC3 Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2475614319
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2475614319
Other Identifiers
ISSN
1341-9625
E-ISSN
1437-7772
DOI
10.1007/s10147-020-01794-8
